Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides

Yoshiaki Miyagi, Teruo Sasatomi, Takashi Mine, Hiroharu Isomoto, Kazuo Shirouzu, Hideaki Yamana, Nobue Imai, Akira Yamada, Kazuko Katagiri, Akira Muto, Shinya Okouchi, Kyogo Itoh, Akira Yamada, Masami Nakagawa, Kyogo Itoh

Research output: Contribution to journalArticlepeer-review

100 Citations (Scopus)

Abstract

The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3109-118 and SART3315-332) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.

Original languageEnglish
Pages (from-to)3950-3962
Number of pages13
JournalClinical Cancer Research
Volume7
Issue number12
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides'. Together they form a unique fingerprint.

Cite this